Zev Sunleaf simplifies the complex process of technology transfer by calling it "matchmaking." This re-frames the goal from a purely transactional one to finding the right strategic partner—be it investors or companies—to advance research from the lab bench to the patient's bedside.

A successful acquisition strategy goes beyond the highest bid. It involves 'thinking like the molecule'—evaluating which buyer has the specific expertise, capabilities, and cultural alignment to best steward the asset's development. This reframes M&A from a financial transaction to a decision about the asset's future.

Beyond funding operations, a strong cash position is a crucial, often unstated, strategic asset for biotechs. It provides significant leverage in partnership discussions with large pharmaceutical companies, allowing smaller firms to reject unfavorable terms and signal they do not need a deal to survive.

Contrary to the focus on large upfront payments, a smarter partnership strategy is to negotiate for a larger share of downstream success through royalties and milestones. This can yield far greater long-term returns if the product succeeds.

Biotech assets have both value ("cheese") and risks ("holes"). Kainova's CEO argues the key to successful deal-making is managing multiple parallel conversations. This lets you identify partners focused on the asset's potential and close when they are ready, rather than getting bogged down by those fixated on the risks.

According to Kainova's CEO, the primary goal of a new biotech platform's first pharma partnership is not financial. It's to secure a prestigious partner name to validate the technology. This external validation, or "PR value," is more critical early on than maximizing the upfront payment, as it builds credibility for future, more lucrative deals.

For pre-revenue biotechs like Voyager, partnering provides non-dilutive capital. More importantly, it de-risks development by sharing costs and leveraging a larger company's resources and expertise. This can increase a drug's probability of success, a crucial factor when most programs fail.

In an industry where technology often fails, Vivtex prioritizes successful execution over deal volume. The CEO stresses that being honest about capabilities and delivering on promises is more crucial for long-term reputation and future partnerships than simply getting an initial deal signed.

Following a cautious 2025, dealmakers now demand tangible evidence of an asset's value. This "proof over promise" approach involves conducting integration planning during due diligence and heavily favoring targets with clearer regulatory pathways to minimize post-acquisition surprises.